- Home
- BY vs IOVA Comparison
BY vs IOVA Comparison
Compare BY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- IOVA
- Stock Information
- Founded
- BY 1914
- IOVA 2007
- Country
- BY United States
- IOVA United States
- Employees
- BY N/A
- IOVA N/A
- Industry
- BY Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BY Finance
- IOVA Health Care
- Exchange
- BY Nasdaq
- IOVA Nasdaq
- Market Cap
- BY 1.1B
- IOVA 1.0B
- IPO Year
- BY 2017
- IOVA N/A
- Fundamental
- Price
- BY $26.24
- IOVA $1.75
- Analyst Decision
- BY Hold
- IOVA Strong Buy
- Analyst Count
- BY 3
- IOVA 9
- Target Price
- BY $33.67
- IOVA $15.50
- AVG Volume (30 Days)
- BY 161.2K
- IOVA 13.9M
- Earning Date
- BY 04-24-2025
- IOVA 05-08-2025
- Dividend Yield
- BY 1.53%
- IOVA N/A
- EPS Growth
- BY N/A
- IOVA N/A
- EPS
- BY 2.69
- IOVA N/A
- Revenue
- BY $379,386,000.00
- IOVA $212,679,000.00
- Revenue This Year
- BY $14.38
- IOVA $182.20
- Revenue Next Year
- BY $5.04
- IOVA $62.10
- P/E Ratio
- BY $9.80
- IOVA N/A
- Revenue Growth
- BY 3.48
- IOVA 11070.12
- 52 Week Low
- BY $21.96
- IOVA $2.70
- 52 Week High
- BY $32.89
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- BY 56.50
- IOVA 23.78
- Support Level
- BY $25.57
- IOVA $3.02
- Resistance Level
- BY $26.61
- IOVA $3.31
- Average True Range (ATR)
- BY 0.60
- IOVA 0.24
- MACD
- BY 0.19
- IOVA -0.09
- Stochastic Oscillator
- BY 85.35
- IOVA 4.81
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.